丙型肝炎治療市場：依藥物類別、給藥途徑、通路及地區分類

丙型肝炎治療市場規模預計將從 2023 年的 86 億美元增加到 2030 年的 113.9 億美元，預測期內複合年成長率為 4.1%。

圖 1. 2023 年按地區分類的C型肝炎藥物全球市場佔有率(%)

丙型肝炎是一種肝臟感染疾病，會導致嚴重的肝損傷。它是由C型肝炎病毒引起的。美國約有 240 萬人受到影響。然而，丙型肝炎很少引起症狀，因此大多數人不會注意到任何症狀。該病毒透過感染者的血液和體液傳播。

丙型肝炎潛伏期。這是從第一次接觸到發病的時期。潛伏期為14至80天，但平均為45天。急性C型肝炎：這是一種短期疾病，病毒進入體內後會持續 6 個月。然後，有些人能夠自行消滅病毒。慢性C型肝炎：大多數感染C型肝炎的人（高達 85%）會進入長期患病階段（超過 6 個月）。這稱為慢性C型肝炎感染，可導致肝癌和肝硬化等嚴重的健康問題。肝硬化。這種疾病會引起發炎，隨著時間的推移，健康的肝細胞會被疤痕組織所取代。發展為肝硬化通常需要大約 20 至 30 年的時間，但飲酒或感染 HIV 可能會更快導致肝硬化。

市場動態：

全球丙型肝炎盛行率的上升預計將在預測期內促進市場成長。例如，根據國家生物技術資訊中心2021年9月18日發布的資料，印度HCV盛行率為0.5%，影響約470萬至1,090萬人。

第1章 研究目的與前提

• 研究目標
• 先決條件
• 簡稱

第2章 市場展望

• 報告說明
  • 市場定義和範圍
• 執行摘要
• Coherent Opportunity Map（COM）

第3章市場動態、法規及趨勢分析

• 市場動態
  • 促進因素
• 全球丙型肝炎盛行率不斷上升
• 政府加大力度
  • 抑制因素
• 負面影響增加
  • 機會
• 增加不同地區的產品供應
• 影響分析
• 主要亮點
• 監管場景
• 產品發布/核准
• PEST分析
• 波特的分析
• 併購場景

第4章丙型肝炎治療藥物市場 -冠狀病毒（COVID-19）大流行的影響

• 新型冠狀病毒感染疾病（COVID-19）的流行病學
• 供需面分析
• 經濟影響

第5章丙型肝炎藥物市場，依藥物類別，2018-2030

• NS3/4A蛋白酶抑制劑
• NS5A抑制劑
• NS5B聚合酶抑制劑
• 組合藥物
• 其他

第6章 2018-2030 年C型肝炎治療藥物市場（依給藥途徑）

• 口服
• 靜脈
• 其他

第7章 2018-2030 年C型肝炎治療藥物市場（依通路）

• 醫院藥房
• 零售藥房
• 網路藥房

第8章 2018-2030 年C型肝炎治療藥物市場（按地區）

• 北美洲
• 美國
• 加拿大
• 歐洲
• 英國
• 德國
• 法國
• 義大利
• 西班牙
• 俄羅斯
• 其他歐洲國家
• 亞太地區
• 中國
• 日本
• 印度
• 澳洲
• ASEAN
• 韓國
• 其他亞太地區
• 拉丁美洲
• 巴西
• 墨西哥
• 阿根廷
• 其他拉丁美洲
• 中東
• GCC
• 以色列
• 其他中東地區
• 非洲
• 南非
• 北非
• 中部非洲

第9章 競爭形勢

• Gilead Sciences
• AbbVie
• Merck & Co
• Bristol-Myers Squibb
• Johnson & Johnson
• Hoffmann-La Roche AG
• Boehringer Ingelheim
• Achillion Pharmaceuticals

第10章

• 調查方法
• 關於出版商

The hepatitis C drugs market size is expected to reach US$ 11.39 billion by 2030, from US$ 8.60 billion in 2023, growing at a CAGR of 4.1% during the forecast period.

Figure 1. Global Hepatitis C Drugs Market Share (%), by Region, 2023

Hepatitis C is a liver infection that can lead to serious liver damage. It's caused by the hepatitis C virus. About 2.4 million people in the U.S. have the disease. But it causes few symptoms, so most of them don't know. The virus spreads through an infected person's blood or body fluids.

Stages of Hepatitis C: Incubation period. This is the time between first exposures to the start of the disease. It can last anywhere from 14 to 80 days, but the average is 45. Acute hepatitis C. This is a short-term illness that lasts for the first 6 months after the virus enters your body. After that, some people who have it will get rid of, or clear, the virus on their own. Chronic hepatitis C. For most people who get hepatitis C - up to 85% - the illness moves into a long-lasting stage (longer than 6 months). This is called a chronic hepatitis C infection and can lead to serious health problems like liver cancer or cirrhosis. Cirrhosis. This disease leads to inflammation that, over time, replaces your healthy liver cells with scar tissue. It usually takes about 20 to 30 years for this to happen, though it can be faster if you drink alcohol or have HIV.

Market Dynamics:

The increasing prevalence of hepatitis C globally is expected to aid in the market growth over the forecast period. For instance, according to the data published by the National Center for Biotechnology Information on September 18, 2021, the prevalence rate of HCV in India is 0.5%, affecting about 4.7 to 10.9 million people.

Hepatitis C Drugs Market Segmentation:

• By Drug Class
  • NS3/4A Protease Inhibitors
  • NS5A Inhibitors
  • NS5B Polymerase Inhibitors
  • Combination Drugs
  • Others
• By Route of Administration
  • Oral Drugs
  • Intravenous
  • Others
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa
• Top Companies in Hepatitis C Drugs Market:
  • Gilead Sciences
  • AbbVie
  • Merck & Co
  • Bristol-Myers Squibb
  • Johnson & Johnson
  • Hoffmann-La Roche AG
  • Boehringer Ingelheim
  • Achillion Pharmaceuticals

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Drug Class
  • Market Snippet, By Route of Administration
  • Market Snippet, By Distribution Channel
  • Market Snippet, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
• Growing Prevalence of Hepatitis C Globally
• Increasing Government Initiatives
  • Restraints
• Increasing Adverse Effects
  • Opportunities
• Increasing Product Availability in Various Regions
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product launch/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario

4. Hepatitis C Drugs Market- Impact of Coronavirus (COVID-19) Pandemic

• COVID-19 Epidemiology
• Supply Side and Demand Side Analysis
• Economic Impact

5. Hepatitis C Drugs Market, By Drug Class, 2018-2030, (US$ Bn)

• Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2019 - 2030
  • Segment Trends
• NS3/4A Protease Inhibitors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
• NS5A Inhibitors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
• NS5B Polymerase Inhibitors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
• Combination Drugs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)

6. Hepatitis C Drugs Market, By Route of Administration, 2018-2030, (US$ Bn)

• Introduction
  • Market Share Analysis, 2023and 2030 (%)
  • Y-o-Y Growth Analysis, 2019- 2030
  • Segment Trends
• Oral Drugs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
• Intravenous
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)

7. Hepatitis C Drugs Market, By Distribution Channel, 2018-2030, (US$ Bn)

• Introduction
  • Market Share Analysis, 2023and 2030 (%)
  • Y-o-Y Growth Analysis, 2019- 2030
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)

8. Hepatitis C Drugs Market, By Region, 2018-2030, (US$ Bn)

• Introduction
  • Market Share Analysis, By Country, 2023and 2030 (%)
  • Y-o-Y Growth Analysis, For Country 2019-2030
  • Country Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
• U.S.
• Canada
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
• U.K.
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
• China
• Japan
• India
• Australia
• ASEAN
• South Korea
• Rest of Asia Pacific
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
• GCC
• Israel
• Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
• South Africa
• North Africa
• Central Africa

9. Competitive Landscape

• Gilead Sciences
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• AbbVie
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Merck & Co
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Bristol-Myers Squibb
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Johnson & Johnson
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Hoffmann-La Roche AG
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Boehringer Ingelheim
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Achillion Pharmaceuticals
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Analyst Views

10. Section

• Research Methodology
• About us